Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019
Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013
Histone deacetylase inhibition promotes fibroblast apoptosis and ameliorates pulmonary fibrosis in mice Source: Eur Respir J 2014; 43: 1448-1458 Year: 2014
Histone deacetylase activity is reduced in COPD. Modulation by theophylline Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: ERS Lung Science Conference 2017 Year: 2017
Oxidative stress-mediated decrease in histone deacetylase activity is attenuated by N-acetyl-L-cysteine but not by Iκ-B kinase inhibition in alveolar epithelial cells Source: Eur Respir J 2004; 24: Suppl. 48, 29s Year: 2004
The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020
Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study Source: Eur Respir J 2011; 37: 129-135 Year: 2011
Decreased histone deacetylase activity in COPD Source: Annual Congress 2008 - Epigenetic modifications in lung disease Year: 2008
LSC Abstract – Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Histone deacetylase activity and gene expression in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 316s Year: 2001
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Histone deacetylases reduction causes defect of Nrf2 response, leading to a reduction of anti-oxidant capacity in COPD Source: Annual Congress 2010 - Pathology and immunology of COPD Year: 2010
Steroids and histone deacetylase in ventilation-induced gene transcription Source: Eur Respir J 2007; 30: 865-877 Year: 2007
Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Single and combined effects of cisplatin, sodium butyrate and sirtinol on covalent histone modifications in human cell lines Source: Eur Respir J 2007; 30: Suppl. 51, 146s Year: 2007
Pharmacological induction of HDAC activity restores steroid function in macrophages subjected to oxidative stress Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
The effects of dexamethasone and IL-1β on histone H3 methylation in A549 cells Source: Eur Respir J 2003; 22: Suppl. 45, 224s Year: 2003
Effect of cigarette smoking on histone deacetylase activity in alveolar macrophages Source: Eur Respir J 2002; 20: Suppl. 38, 416s Year: 2002
LSC - 2017 - Re-education of tumor-associated macrophages by modulating histone deacetylases in lung cancer Source: International Congress 2017 – Basic research in lung cancer: a scientific potpourri from genetic alterations to immune cells Year: 2017